Integra Therapeutics Will Receive 10.5 Million for Its Ficat Platform

Integra Therapeutics conquers Europe. The company dedicated to the creation of genetic writing tools will receive a grant of 2.5 million euros and a direct investment of up to eight million euros from the European Commission (EC) through the European Innovation Council (EIC) Accelerator program.

Out of 969 deeptech companies, the EC has selected only 68 to benefit from the funding. EIC Accelerator is the only programme that combines grants and capital for European deeptech start-ups.

The European Commission has a total of €411 million available for those companies selected to receive this funding. €165 million will be allocated in grants and a further €245 million in equity. 96% of all selected companies will receive the blended finance option, which is a combination of grants and equity investments.

Ficat is a platform, developed by Integra therapeutics, aimed at solving the current limitations in gene writing: size, precision and stability

The EC will invest in the capital of Integra Therapeutics in 2025 with a stake that could reach eight million euros to advance the clinical development of a gene therapy product. In this case , the company will allocate the 2.5 million euros to subsidize the marketing of its Ficat platform .

“The funding from EIC Accelerator is a major boost for Integra Therapeutics and the Ficat gene writing platform as it will trigger the development of the first therapeutic product in preclinical and clinical regulatory phases for a disease with a high unmet medical need in children,” explains Dr. Avencia Sánchez Mejías, CEO and co-founder of Integra Therapeutics.

Integra Therapeutics is a biotechnology company that creates genetic writing tools to improve the safety and efficacy of advanced therapies. Integra was founded in 2020 as a spin-off of Pompeu Fabra University (UPF) by Dr. Marc Güell and Dr. Avencia Sánchez-Mejías and is based in Barcelona.

__

(Featured image by Warren Umoh via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us